RBC Capital Downgrades Human Genome Sciences (HGSI) to Sector Perform
Tweet Send to a FriendGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HGSI Now!
RBC Capital downgraded Human Genome Sciences (NASDAQ: HGSI) from Outperform to Sector Perform, price target lowered from $15 to $10.
For an analyst ratings summary and ratings history on Human Genome Sciences click here. For more ratings news on Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $8.92 yesterday, with a 52 week range of $6.51-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Human Genome Sciences click here. For more ratings news on Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $8.92 yesterday, with a 52 week range of $6.51-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Jefferies Buyers of Jack In The Box (JACK) on Solid Results
- UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
